Aldevron News

Aldevron Honored by Goldman Sachs for Entrepreneurship

Michael Chambers, Founder and CEO, Among 100 Most Intriguing Entrepreneurs at 2018 Builders + Innovators Summit

Goldman Sachs (NYSE:GS) is recognizing Aldevron CEO and Founder Michael Chambers as one of the 100 Most Intriguing Entrepreneurs at the 2018 Builders + Innovators Summit in Santa Barbara, California.

Read More

Genprex™ Taps Aldevron to Supply TUSC2 Plasmid DNA for Oncoprex™ Clinical Development Program

Newly manufactured plasmids will be applied in clinical trials evaluating Oncoprex in combination with targeted therapies and immunotherapies

Austin, Texas, Cambridge, Mass. and Fargo, N.D. – September 26, 2018 – Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, has signed an agreement with Aldevron, a leading contract manufacturing organization, to supply TUSC2 (Tumor Suppressor Candidate2) plasmid DNA for use in Genprex’s clinical development program evaluating its immunogene therapy Oncoprex for the treatment of non-small cell lung cancer.

Read More

Aldevron hires six

Aldevron has added six new employees in its Fargo location, including Steve Chalfant, Pragya Dahal, Maureen Krogstad, Audra Puppe, David Fellen and Michael Schmidt.

Read More